Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $20
Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and raises the price target from $19 to $20.
Canaccord Genuity Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $26
Canaccord Genuity analyst Sumant Kulkarni maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $24 to $26.
Cantor Fitzgerald Maintains Overweight on ACADIA Pharmaceuticals, Raises Price Target to $33
Cantor Fitzgerald analyst Charles Duncan maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and raises the price target from $28 to $33.
Acadia Pharma’s Rett Syndrome Drug Becomes First FDA-Approved Treatment
The FDA has approved Acadia Pharmaceuticals Inc’s (NASDAQ:ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of…
Mizuho Reiterates Neutral on ACADIA Pharmaceuticals, Maintains $19 Price Target
Mizuho analyst Uy Ear reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and maintains $19 price target.
Citigroup Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $19.4
Citigroup analyst Neena Bitritto-Garg maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $19 to $19.4.
Oppenheimer Maintains Perform on ACADIA Pharmaceuticals, Raises Price Target to $17
Oppenheimer analyst Jay Olson maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Perform and raises the price target from $16 to $17.
Citigroup Maintains Neutral on ACADIA Pharmaceuticals, Raises Price Target to $19
Citigroup analyst Neena Bitritto-Garg maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and raises the price target from $17 to $19.
Acadia Pharmaceuticals Highlights Publication Of NUPLAZID analysis In Drug Safety
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced today that the journal Drug Safety published results from a retrospective analysis finding a lower mortality risk in patients with Parkinson's disease
Guggenheim Upgrades ACADIA Pharmaceuticals to Buy, Announces $22 Price Target
Guggenheim analyst Yatin Suneja upgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Neutral to Buy and announces $22 price target.